Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of LV232 capsules for major depressive disorder
CTR20250116Phase 2Active
- Sponsor
- Vigonvita Life Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LV232 in major depressive disorder (MDD), sponsored by Vigonvita Life Sciences. Started Apr 2025; status: active.
02
Drugs
LV232
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20250116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250116.